Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2Melanoma 2Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Hematologic Neoplasms 1Cytopenia 1Coronavirus Infections 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22Thiotepa 20Sirolimus 20Azacitidine 20venetoclax 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × HuMax-IL8 × Clear all
NCT04347226 2025-05-22

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Columbia University

Phase 2 Terminated
43 enrolled 14 charts
Other hematologic neoplasm

COVID-19, Coronavirus Infections, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡